EUCTR2006-005728-17-IT
Active, not recruiting
Not Applicable
Hormone-refractory Prostate cancer first Line Intermittent Taxotere and Estramustine. - ND
AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO0 sites128 target enrollmentJanuary 16, 2007
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate cancer.
- Sponsor
- AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO
- Enrollment
- 128
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1 histologically proven diagnosis of prostate cancer 2 previous therapy with LHRH\-analogue 3 PSA value rise during second line hormonal manipulation 4 performance status less than ECOG 2 5 life expectancy more than 12 weeks 6 adequate bone marrow function 7 written consent informed 8 patients ability to fill the quality of life questionnaire
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •1 disease progression without PSA rise 2 active infection 3 previous chemotherapy for prostate cancer 4 non adequate liver or renal functions 5 major diseases limiting chemotherapy 6 major cardiovascular diseases
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 TrialProstate cancerTherapeutic area: Diseases [C] - Neoplasms [C04]CTIS2022-501551-90-00Gasthuiszusters Antwerpen493
Unknown
Not Applicable
Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving ChemotherapyHormone Refractory Prostate CancerProstate CancerNCT00133900Immunicon276
Unknown
Phase 2
Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate CancerProstate CancerNCT00657982Sheba Medical Center15
Completed
Phase 1
Radionuclide therapy using Lutetium-177 prostate specific membrane antigen (PSMA): a pilot study in men with castrate-resistant prostate cancer (LuPSMA trial)Prostate CancerCancer - ProstateACTRN12615000912583Peter MacCallum Cancer Centre30
Completed
Not Applicable
Outcome study of hormonal therapy for prostate cancer in JapaJPRN-C000000252J-CaP study group24,000